RISEDRONIC ACID

Details

Stereochemistry	ACHIRAL
Molecular Formula	C7H11NO7P2
Molecular Weight	283.1123
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(CC1=CN=CC=C1)(P(O)(O)=O)P(O)(O)=O

InChI

InChIKey=IIDJRNMFWXDHID-UHFFFAOYSA-N

InChI=1S/C7H11NO7P2/c9-7(16(10,11)12,17(13,14)15)4-6-2-1-3-8-5-6/h1-3,5,9H,4H2,(H2,10,11,12)(H2,13,14,15)

HIDE SMILES / InChI

Molecular Formula	C7H11NO7P2
Molecular Weight	283.1123
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020835s048lbl.pdf
Curator's Comment: description was created based on several sources, including: https://www.drugs.com/mtm/risedronate.html http://www.wikidoc.org/index.php/Risedronate http://www.rxlist.com/actonel-drug.htm

Risedronic acid is a pyridinyl bisphosphonate that inhibits osteoclast-mediated bone resorption and modulates bone metabolism. The action of risedronate on bone tissue is based partly on its affinity for hydroxyapatite, which is part of the mineral matrix of bone. Risedronate also targets farnesyl pyrophosphate (FPP) synthase. It is FDA approved for the treatment of postmenopausal osteoporosis, osteoporosis in men, glucocorticoid-induced osteoporosis and Paget’s disease. Calcium, antacids, or oral medications containing divalent cations interfere with the absorption of Risedronic acid. Common adverse reactions include rash, abdominal pain, constipation, diarrhea, indigestion, nausea, backache, urinary tract infectious disease and influenza-like illness.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Hydroxyapatite crystals 4 Target ID: Hydroxyapatite crystals Sources: https://www.ncbi.nlm.nih.gov/pubmed/25568655	Binding Agent 1076
Farnesyl diphosphate synthase 28 Target ID: CHEMBL1782 Sources: http://www.drugbank.ca/drugs/DB00884 \| https://www.ncbi.nlm.nih.gov/pubmed/25568655	Inhibitor 8504		3.9 nM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Postmenopausal osteoporosis 59 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020835s048lbl.pdf	Primary	Approved 8583	ACTONEL Approved Use ACTONEL is indicated for the treatment and prevention of osteoporosis and Paget’s disease of bone in men and women. Launch Date 1998
Glucocorticoid-induced osteoporosis 11 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020835s048lbl.pdf	Primary	Approved 8583	ACTONEL Approved Use ACTONEL is indicated for the treatment and prevention of glucocorticoid-induced osteoporosis in men and women who are either initiating or continuing systemic glucocorticoid treatment (daily dosage of ≥ 7.5 mg prednisone or equivalent) for chronic diseases. Launch Date 1998
Paget’s disease of bone 13 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020835s048lbl.pdf	Primary	Approved 8583	ACTONEL Approved Use ACTONEL is indicated for treatment of Paget’s disease of bone in men and women. Launch Date 1998
Increase bone mass in men with osteoporosis 4 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020835s048lbl.pdf	Primary	Approved 8583	ACTONEL Approved Use ACTONEL is indicated for treatment to increase bone mass in men with osteoporosis. Launch Date 1998

C_max

Value	Dose	Co-administered	Analyte	Population
2.05 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/14999521	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:		RISEDRONATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
6.49 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/14999521	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:		RISEDRONATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
1.61 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/14999521	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:		RISEDRONATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY510605	https://www.001chemical.com/chem/1197-18-8
3B Scientific (Wuhan) Corp	3B3-004681	http://www.3bsc.com/index/pro_info.php?id=26567
AA Blocks	AA00HAKO	https://www.aablocks.com/goods/Goods/detail?id=AA00HAKO
Aaron Chemicals	AR00HBCG	http://www.aaronchem.com/105462-24-6
abcr GmbH	AB504521	http://www.abcr.com/shop/en/AB504521
Acadechem	ACDS-026260	http://www.acadechemical.com/product/100959
Achemo Scientific Limited	AC-15534	http://www.achemo.com/product_view.asp?ID=5424
Achemtek	0104-019190	http://www.achemtek.com/105462-24-6
Adooq BioScience	A11675	https://www.adooq.com/risedronic-acid-actonel.html
AHH Chemical co.,ltd	MT-15499	http://www.ahhchemical.com/product/MT-15499.html
AK Scientific, Inc. (AKSCI)	2689AH	http://www.aksci.com/item_detail.php?cat=2689AH
AK Scientific, Inc. (AKSCI)	I802	http://www.aksci.com/item_detail.php?cat=I802
Ambeed	A471285	https://www.ambeed.com/products/105462-24-6.html
Angene	AGN-PC-04XTDK	http://www.angenechemical.com/productshow/AGN-PC-04XTDK.html
ApexBio Technology	B1826	http://www.apexbt.com/risedronate.html
AstaTech, Inc.	67956	http://www.astatechinc.com/CPSResult.php?CRNO=14010
Aurum Pharmatech LLC	M-1366	http://www.Aurumpharmatech.com/Product/ProductDetails/M_1366
AvaChem Scientific	2610A	http://www.avachem.com/productSearch.asp?2610A
BioChemPartner	BCP13805	http://www.biochempartner.com/105462-24-6-BCP13805
BioCrick	BCC4711	http://www.biocrick.com/Risedronate-BCC4711.html
BLD Pharm	BD17422	http://www.bldpharm.com/products/105462-24-6.html
Boerchem	BC206977	http://www.boerchem.com/?product_34916.html
Capot Chemical	14002	http://www.capotchem.com/en/14002.htm
Capot Chemical	PubChem14002	http://www.capotchem.com/en/14002.htm
Chem Scene	CS-1964	http://www.chemscene.com/105462-24-6.html
Chemenu	CM110535	http://www.chemenu.com/products/CM110535
ChemMol	30103518	http://www.chemmol.com/chemmol/30103518.html
ChemMol	44002664	http://www.chemmol.com/chemmol/44002664.html
ChemMol	49408876	http://www.chemmol.com/chemmol/49408876.html
Chemspace	CSSB00000692965	https://chem-space.com/CSSB00000692965
Clearsynth	CS-O-11736	https://www.clearsynth.com/en/CSO11736.html
CSNpharm	CSN12477	https://www.csnpharm.com/products/risedronate.html
DC Chemicals	DCAPI1012	http://www.dcchemicals.com//product_show-Risedronic_acid_Actonel_.html
Enamine	Z2684418685	https://www.enaminestore.com/catalog/Z2684418685
Finetech	FT-0642593	http://www.finetechnology-ind.com/prod/detail/pub/105462-24-6.html
Glentham Life Sciences	GP6400	http://www.glentham.com/products/product/GP6400/
Hairui	HR124405	http://www.hairuichem.com/en/product/1197-18-8.html
Huateng Pharma	F80017483	http://en.huatengsci.com/product/Risedronic-acid-monohydrate.html
LGC Standards	MM0777.09-0025	https://www.lgcstandards.com/US/en/p/MM0777.09-0025
MedChem Express	HY-B0148	https://www.medchemexpress.com/Risedronic-acid.html
Molcore	MC510605	https://www.molcore.com/product/1197-18-8
MuseChem	A000751	https://www.musechem.com/product/A000751.html
OChem	3875	http://www.ocheminc.com/index.php?act=psearch&pid=462R246
Selleck Chemicals	S1874	http://www.selleckchem.com/products/risedronic-acid-actonel.html
Sinfoo Biotech	S010603	http://www.sinfoobiotech.com/product/1014001
Smolecule	S591430	https://www.smolecule.com/products/s591430
THE BioTek	bt-311863	https://www.thebiotek.com/product/others/bt-311863
Yuhao Chemical	XJ6805	http://www.chemyuhao.com/105462-24-6.html

PubMed

Title	Date	PubMed
The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis.	2002-08	12085156
Activity of bisphosphonates against Trypanosoma brucei rhodesiense.	2002-07-04	12086478
Bone quality: getting closer to a definition.	2002-07	12096827
Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized minipigs as measured by three-dimensional microcomputed tomography.	2002-07	12096826
Sequential treatment with basic fibroblast growth factor and PTH is more efficacious than treatment with PTH alone for increasing vertebral bone mass and strength in osteopenic ovariectomized rats.	2002-07	12072383
The potential of parathyroid hormone as a therapy for osteoporosis.	2002-06-26	12081255
Treatment of postmenopausal osteoporosis.	2002-06-08	12076571
Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date.	2002-05-28	12054412
Osteoporosis in men.	2002-05-25	12025803
The bisphosphonate zoledronic acid impairs Ras membrane [correction of impairs membrane] localisation and induces cytochrome c release in breast cancer cells.	2002-05-06	11986784
Gateways to clinical trials.	2002-05	12092009
Risedronate: a new oral bisphosphonate.	2002-05	12075950
The cost utility of bisphosphonate treatment in established osteoporosis.	2002-05	11978902
[Episcleritis secondary to risedronate].	2002-04-27	12015954
[When osteoporosis first manifests itself. Without therapy the next fracture threatens].	2002-04-04	12014286
[Osteoporosis - Evidence based therapy].	2002-04	11930292
Risedronate for the prevention of fractures in postmenopausal osteoporosis.	2002-04	11918518
[Risedronate, a new diphosphonate in osteoporosis and Paget's disease].	2002-03-02	11913075
[Risedronate: clinical usage].	2002-03	11979951
Risedronate for the prevention and treatment of corticosteroid-induced osteoporosis.	2002-03	11895066
Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials.	2002-03	11888030
Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint.	2002-02	11844743
Risedronate treatment and extended fracture protection in postmenopausal women.	2002-01-17	11791630
Medical treatment of osteoporosis--increasing options.	2002-01	11885495
Therapies to improve bone mineral density and reduce the risk of fracture: clinical trial results.	2002-01	11829081
Risedronate reduces the risk of first vertebral fracture in osteoporotic women.	2002	12107665
The underuse of therapy in the secondary prevention of hip fractures.	2002	11929323
Actions of bisphosphonates in animal models of breast cancer.	2002	11879558
Development of bisphosphonates.	2002	11879557
Direct effects of bisphosphonates on breast cancer cells.	2002	11879555
Effect of vitamin D on bone mineral density of elderly patients with osteoporosis responding poorly to bisphosphonates.	2002	11860614
[Therapy of osteoporosis. Risk factors alone are not an indication].	2001-12-06	11813710
Risedronate for the prevention and treatment of postmenopausal osteoporosis: results from recent clinical trials.	2001-12	11846337
Bisphosphonates for the treatment of postmenopausal osteoporosis: clinical studies of etidronate and alendronate.	2001-12	11846336
Review of risedronate in the treatment of osteoporosis.	2001-12	11825332
Anabolic agents for treating postmenopausal osteoporosis.	2001-12	11809001
Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis.	2001-12	11728926
[Economic aspects of osteoporosis therapy. What does a prevented fracture cost?].	2001-11-22	11791359
A method to assess the proportion of treatment effect explained by a surrogate endpoint.	2001-11-15	11746311
[Alternatives to hormonal treatment for the prevention of postmenopausal osteoporosis: the bisphosphonates].	2001-11	11770280
Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage.	2001-11	11768198
The role of serial bone mineral density testing for osteoporosis.	2001-11	11747684
Role of alendronate and risedronate in preventing and treating osteoporosis.	2001-11	11718433
[Osteoporosis. Fracture as alarm signal].	2001-10-11	11721665
Tolerability of risedronate in postmenopausal women intolerant of alendronate.	2001-10	11820707
Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy.	2001-10	11730260
Alendronate for the treatment of osteoporosis in men.	2001-10	11730259
Paget's disease of the spine and its management.	2001-10	11718191
Ocular adverse effects of alendronic acid.	2001-06	11718170
Comparison insight dual X-ray absorptiometry (DXA), histomorphometry, ash weight, and morphometric indices for bone evaluation in an animal model (the orchidectomized rat) of male osteoporosis.	2001-01	12037621

Patents

Sample Use Guides

In Vivo Use Guide

Treatment of Postmenopausal Osteoporosis: 5 mg daily, 35 mg once-a-week, 75 mg two consecutive days each month, 150 mg once-a-month. Prevention of Postmenopausal Osteoporosis: 5 mg daily, 35 mg once-a-week. Men with Osteoporosis: 35 mg once-a-week. Glucocorticoid-Induced Osteoporosis: 5 mg daily. Paget’s Disease: 30 mg daily for 2 month.

Route of Administration: Oral

In Vitro Use Guide

The antimalarial activities of risedronate, one of the most potent bisphosphonates clinically used to treat bone resorption diseases, against blood stages of Plasmodium falciparum (50% inhibitory concentration [IC50] of 20.3±1.0 μM).

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:21:19 GMT 2025` Edited by `admin` on `Mon Mar 31 18:21:19 GMT 2025`
Record UNII	KM2Z91756Z
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

RISEDRONIC ACID

Official Name

English

RISEDRONATE

Preferred Name

English

M05BA07

Code

English

RISEDRONIC ACID [MART.]

Common Name

English

2-(3-PYRIDINYL)-1-HYDROXYETHANE DIPHOSPHONIC ACID

Systematic Name

English

Risedronic acid [WHO-DD]

Common Name

English

RISEDRONIC ACID [HSDB]

Common Name

English

RISEDRONIC ACID [MI]

Common Name

English

RIDRON

Brand Name

English

risedronic acid [INN]

Common Name

English

RISEDRONATE [VANDF]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QM05BA07